In a subset analysis of EGFR wild-type tumors , PFS for erlotinib versus docetaxel was @ v @ months ( HR , @ ; @ % CI , @ to @ ; P = @ ) , and OS was @ v @ months ( HR , @ ; @ % CI , @ to @ ; P = @ ) , respectively .